Skip Navigation Links
Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) CompletelyResected Non-small Cell Lung Cancer
Overall Recruitment Status: Active, currently enrolling
Official Title
A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 IIIIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Region Sponsors
Acronym KP IRB No.
CANOPY-A 1709842
Study Type Phase
Clinical Trial Phase III
Study Population Description
The primary purpose of the study is to compare the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II -IIIA and the subset of IIIB (T>5cm N2 disease) completely resected (R0) non-small cell lung cancer (NSCLC).
Detailed Description
Gender Age Limit
Male & Female
Inclusion Criteria
  • Have completely resected (R0) NSCLC AJCC/UICC v. 8 stage IIA-IIIA and IIIB (N2 disease only) OR have NSCLC Stage IIA-IIIA, IIIB (N2 disease only) and are candidates for complete resection surgery
  • Must have recovered from all toxicities related to prior systemic therapy to grade = 1 (CTCAE v 4.03). Exception to this criterion: subjects with any grade of alopecia and grade 2 or less neuropathy are allowed to enter the study
  • Have ECOG performance status (PS) of 0 or 1
Exclusion Criteria
  • Have unresectable or metastatic disease, positive microscopic margins on the pathology report, and/or gross disease remaining at the time of surgery
  • Have received neoadjuvant chemotherapy or neoadjuvant radiotherapy
  • Presence or history of a malignant disease, other than the resected NSCLC, that has been diagnosed and/or required therapy within the past 3 years Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, completely resected carcinoma in situ of any type and hormonal maintenance for breast and prostate cancer > 3 years
  • Have a history of current diagnosis of cardiac disease
  • Have uncontrolled diabetes

Keywords and/or Specific Medical Conditions
  • Oncology (Adult)
KP Clinical Facility
  • Moanalua Medical Center and Clinic
Clinical Area
  • Oncology (Adult)

Principal Investigator:
Jennifer Carney, MD
Contact Information:
- Shelley Clark, RN
-Moanalua Medical Center and Clinic

Do you want to receive
Email Alerts?

Sign Up Here!

Regional Research Sites: